Abstract
We recently showed that suramin treatment prevents the onset of renal fibrosis in a model of obstructive nephropathy induced by unilateral ureteral obstruction (UUO). In this study, we further assessed the effect of delayed administration of suramin on the progression of tubulointerstitial fibrosis. Mice were given a single dose of suramin at 20 mg/kg starting at day 3 of obstruction, and kidneys were harvested after an additional 7 or 14 days of obstruction. Suramin completely blocked further increase in expression of type I collagen and fibronectin and largely suppressed expression of α-smooth muscle actin (α-SMA) in both treatment groups. UUO injury induced phosphorylation of Smad-3, a key mediator of transforming growth factor-β (TGF-β) signaling, epidermal growth factor receptor, and platelet-derived growth factor receptor after 3 days and further increased at 10 days after UUO injury. When suramin was administered at 3 days after obstruction, phosphorylation of these molecules was not further increased in the obstructed kidney. Suramin treatment also inhibited activation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1 and 2, two signaling pathways associated with renal fibrogenesis. Furthermore, delayed application of suramin suppressed TGF-β1-induced expression of α-SMA and fibronectin in cultured renal interstitial fibroblasts. These results indicate that administration of suramin is effective in attenuating the progression of renal fibrosis after injury and suggest the potential clinical application of suramin as an antifibrotic treatment in patients with chronic kidney disease.
Footnotes
This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants DK-071997, DK-085065] (to S.Z.); and by the Shanghai Scientific Committee, China [no. 10410701400 (to H.Y.)
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.111.181727.
-
ABBREVIATIONS:
- CKD
- chronic kidney disease
- TGF-β
- transforming growth factor-β
- PDGFR
- platelet-derived growth factor receptor
- EGFR
- epidermal growth factor receptor
- STAT3
- signal transducer and activator of transcription 3
- ERK1/2
- extracellular regulated kinase 1 and 2
- ECM
- extracellular matrix
- ESRD
- end stage of renal disease
- UUO
- unilateral ureteral obstruction
- p
- phospho
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase
- α-SMA
- α-smooth muscle actin
- NRK-49F
- normal rat kidney fibroblast
- FBS
- fetal bovine serum.
- Received March 17, 2011.
- Accepted May 13, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|










